{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Foreign Desk", "lead_paragraph": "A major Indian drug company announced yesterday that it would start making a generic version of Tamiflu, the anti-influenza drug that is in critically short supply in the face of a possible epidemic of avian flu. ''Right or wrong, we're going to commercialize and make oseltamivir,'' said Dr. Yusuf K. Hamied, chairman of Cipla of Bombay, using the drug's generic name and acknowledging that he might face a fight in the Indian courts with Roche, the Swiss pharmaceutical giant that holds the patent.", "headline": {"main": "Indian Company to Make Generic Version of Flu Drug Tamiflu"}, "abstract": "Cipla of Bombay, major Indian drug company, says it would start making generic version of Tamiflu, anti-infuenza drug in critically short supply, in face of possible epidemic of avian flu; Dr Yusuf K Hamied, Cipla's chairman, acknowledges he might face fight in Indian courts with Roche, Swiss pharmaceutical giant that holds patent; patent laws across world allow governments to cancel patents during emergencies and either buy generics or force patent holders to license their formulas to rivals; Roche has been under growing pressure from several countries and United Nations Sec Gen Kofi Annan to license generic versions of Tamiflu (M)", "print_page": "3", "word_count": 597, "_id": "4fd251088eb7c8105d7f4dbc", "snippet": "A major Indian drug company announced yesterday that it would start making a generic version of Tamiflu, the anti-influenza drug that is in critically short supply in the face of a possible epidemic of avian flu.     ''Right or wrong, we're going to...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9C04E6D7173FF937A25753C1A9639C8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "HAMIED, YUSUF K"}, {"name": "persons", "value": "ANNAN, KOFI"}, {"name": "organizations", "value": "ROCHE AG"}, {"name": "organizations", "value": "CIPLA LTD"}, {"name": "organizations", "value": "UNITED NATIONS"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "INFLUENZA"}, {"name": "subject", "value": "AVIAN INFLUENZA"}, {"name": "subject", "value": "TAMIFLU (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "INVENTIONS AND PATENTS"}], "byline": {"person": [{"qualifier": "Jr", "firstname": "Donald", "middlename": "G.", "lastname": "McNEIL", "rank": 1, "role": "reported", "organization": ""}], "original": "By DONALD G. McNEIL Jr"}, "document_type": "article", "pub_date": "2005-10-14T00:00:00Z", "section_name": "Technology; World; Health"}], "meta": {"hits": 1, "offset": 0, "time": 44}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}